
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating ...
Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trial Phase 2 clinical trial initiation anticipated in first half of 2026 Pediatric cardiomyopathies affect at least 100,000 children …